At CORNEA_project, our values are rooted in continuous innovation, strategic collaboration, and sustainable growth within the field of ophthalmology. Our primary objective is to lead the market by developing disruptive technologies that revolutionize the diagnosis and treatment of corneal diseases such as keratoconus and Dry Eye Syndrome. To achieve this, the company has adopted a strategy centered around three key pillars:

1. Technological Innovation Through Molecular Biomarkers

We invest in cutting-edge R&D to develop pioneering solutions that enable ophthalmologists to perform accurate diagnoses and prognoses of ophthalmic diseases. Our patented advanced molecular analysis methods and Point-of-Care (PoC) devices bring state-of-the-art biotechnology directly to ophthalmology practices, enhancing clinical efficiency and patient care.

2. Strategic Alliances and Collaborations

We actively foster partnerships with leading academic institutions, hospitals, and research centers to accelerate innovation and validate our technologies. These collaborations strengthen our position in the ophthalmology market and ensure the scientific rigor of our advancements.       

3. Commercialization and International Expansion

Our approach includes building a robust portfolio of patented assets, covering both the minimally invasive sample collection method and the biomarkers analyzed through our multiplex PoC device. To support this expansion, the company will launch its final funding round in September 2025, with plans to showcase its results during the ESCRS Congress. This strategy positions CORNEA_project as a global leader in the field.